NTPC may advance after good Q2 result

NTPC reported 36.37% rise in net profit to Rs 3400.84 crore on 5.66% rise in total income to Rs 26266.05 crore in Q2 September 2019 over Q2 September 2018.

Adani Ports & Special Economic Zone, Coal India and Hindalco Industries will announce their quarterly results today, 11 November 2019.

Nestle India's net profit rose 33.5% to Rs 595.41 crore on 9.5% increase in net sales to Rs 3,199.31 crore in Q3 September 2019 over Q3 September 2018.

Bank of Baroda registered 73.2% increase in net profit to Rs 736.68 crore in Q2 September 2019 from Rs 425.38 crore in Q2 September 2018. Total income rose 64.5% to Rs 22,097.91 crore in Q2 September 2019 over Q2 September 2018.

Tata Power Company's consolidated net profit slipped 19.5% to Rs 270.17 crore on 4.4% increase in net sales to Rs 7,677.82 crore in Q2 September 2019 over Q2 September 2018. Net profit declined mainly due to favourable tariff order in Mumbai licensed area in the previous year.

Infosys said that the company (along with certain current and former key managerial personnel) have submitted applications (Applications) with the Registrar of Companies, Karnataka, Bengaluru under Section 441 of the Companies Act, 2013 (Act) for compounding of certain alleged offences that pertain to matters relating to the severance agreement executed with the former Chief Financial Officer of the Company in October 2015 (Agreement).

Through the compounding process, the Company seeks to resolve the alleged offences under the Act relating to: (i) the Company not seeking prior and separate approvals required as per the Act from the Nomination and Remuneration Committee, Audit Committee and the Board of Directors of the Company with regard to the Agreement; and (ii) not making the requisite disclosures. The company has applied for compounding to put this legacy matter to rest, Infosys said.

Lupin announced that it has received approval for its Zileuton Extended-Release Tablets, 600 mg, from the United States Food and Drug Administration (U.S. FDA), to market a generic equivalent of Zyflo CR Extended-Release Tablets, 600 mg, of Chiesi USA, Inc.

Ashok Leyland reported a 92.61% slump in net profit to Rs 39 crore for the second quarter ended 30 September 2019. The commercial vehicles maker had reported a net profit of Rs 528 crore in Q2 September 2018. Revenue stood at Rs 3,929 crore for the second quarter, down 48.45% compared with Rs 7,621 crore in the year-ago period.

Dr. Lal PathLabs recorded 41.48% jump in consolidated profit after tax to Rs 80.50 crore on 15.15% increase in revenues to Rs 365.60 crore in Q2 September 2019 over Q2 September 2018.

CRISIL reported 16.80% rise in consolidated net profit to Rs 105.13 crore in Q3 September 2019 as against Rs 90.01 crore in Q3 September 2018. Consolidated net sales rose 2.45% to Rs 435.88 crore in Q3 September 2019 as against Rs 425.46 crore in Q3 September 2018.

Aditya Birla Capital reported 37.46% rise in net profit to Rs 255.78 crore on 11.18% rise in total income to Rs 4056.31 crore in Q2 September 2019 over Q2 September 2018.

KEC International reported a 42% increase in consolidated profit after tax to Rs 139 crore in Q2 September 2019 as against Rs 98 crore in Q2 September 2018. Revenues increased by 17% to Rs 2809 crore in Q2 September 2019 as against Rs 2408 crore in Q2 September 2018.

Powered by Capital Market - Live News